Nitazoxanide

Drug Profile

Nitazoxanide

Alternative Names: Alinia; Colufase; Cryptaz; Daxon; Heliton; Nitazoxanide controlled-release tablets - Romark; Nitazoxanide CR 675mg tablets - Romark; NT-300; NT-675; NTZ; PH 5776; Tizoxanide

Latest Information Update: 08 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Romark Laboratories
  • Developer Chugai Pharmaceutical; Romark Laboratories
  • Class Anthelmintics; Antidiarrhoeals; Antiprotozoals; Antivirals; Small molecules; Thiazoles
  • Mechanism of Action EIF-2 kinase modulators; HN protein inhibitors; Oxidoreductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amoebiasis; Giardiasis; Cryptosporidiosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryptosporidiosis; Giardiasis; Helminthiasis; Protozoan infections
  • Phase III Influenza virus infections
  • Phase II/III Hepatic encephalopathy
  • Phase II Respiratory syncytial virus infections
  • Suspended Hepatitis C
  • No development reported Clostridium infections; Crohn's disease; Rotavirus infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 27 Nov 2015 Romark Laboratories plans a phase III trial for Influenza virus infections (In adolescents, In adults) in USA (PO, Tablet) (NCT02612922)
  • 12 Oct 2015 Phase-II clinical trials in Respiratory syncytial virus infections in USA (PO, suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top